Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
pSivida Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
pSivida Corp, Medical Devices Deals, 2011 to YTD 2017 10
pSivida Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
pSivida Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
pSivida and Nicox Enter into Agreement 12
pSivida Enters into Agreement with Major Global Pharmaceutical Company 13
Equity Offering 14
pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 14
pSivida Raises USD17.8 Million in Public Offering of Shares 15
pSivida Raises USD7 Million in Private Placement of Shares 17
pSivida Announces Private Placement Of Shares For US$19 Million 18
pSivida Completes Public Offering Of Shares For US$10.8 Million 19
pSivida Completes Private Placement Of Units For US$5.4 Million 20
pSivida Completes Registered Direct Offering Of Units For US$11 Million 21
pSivida Corp – Key Competitors 23
pSivida Corp – Key Employees 24
pSivida Corp – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2017: pSivida Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution 26
Sep 11, 2017: pSivida Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results 27
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track 28
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results 29
May 04, 2017: pSivida Q3 net loss increases 30
Feb 07, 2017: pSivida Reports Fiscal 2017 Second Quarter and First Half Results 31
Nov 07, 2016: pSivida Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline 33
Sep 12, 2016: PSIVIDA Provides Company Update And Reports Fourth Quarter And FY 2016 Results 35
Feb 08, 2016: Psivida Provides Company Update And Reports Second Quarter FY 201 6 Results 37
Corporate Communications 39
Jun 28, 2017: pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson 39
Sep 27, 2016: pSivida Strengthens Board of Directors With Leading Ophthalmologist 40
Aug 03, 2016: pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer 41
Product News 42
10/26/2016: Alimera Sciences Begins Selling ILUVIEN in the Middle East 42
09/06/2016: Alimera Sciences Announces 23 Clinical Presentations and a Sponsored Symposium at 16th EURETINA Congress 43
08/09/2017: Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting 45
08/09/2016: Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting 46
08/07/2017: Alimera Sciences CEO Dan Myers to Present U.S. Real-World ILUVIEN Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017 47
07/25/2017: Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN Treatment 48
07/18/2017: Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences 49
07/17/2017: Real-world Data Reveal Real-world Benefits Of Iluvien Treatment 50
07/12/2017: Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN 51
05/11/2016: Alimera Sciences’ ILUVIEN Data Presented at SFO 2016 52
05/06/2016: Alimera Sciences ILUVIEN Data Presented At 2016 ARVO 53
05/01/2017: Alimera Sciences Announces Data From 27 ILUVIEN Studies to Be Presented at 2017 ARVO 54
03/15/2017: Abstract on pSivida’s Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 57
02/06/2017: Alimera Sciences Announces the Reimbursement of ILUVIEN in Italy 58
01/04/2016: Alimera Sciences Announces ILUVIEN J Code J7313 Is Now Active 59
Product Approvals 60
Feb 22, 2017: Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien in Canada 60
May 02, 2016: pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe 61
Clinical Trials 62
Jul 19, 2017: Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN Registry Safety Study in the U.K. 62
May 08, 2017: Durasert Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months 63
Oct 04, 2016: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target 64
Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting 65
Aug 09, 2016: Primary Endpoint Met in pSivida’s Utilization Study of New Medidur Inserter with Smaller Diameter Needle 66
Jul 27, 2016: pSivida’s Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) 67
Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve 68
Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
pSivida Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
pSivida Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
pSivida Corp, Deals By Therapy Area, 2011 to YTD 2017 9
pSivida Corp, Medical Devices Deals, 2011 to YTD 2017 10
pSivida Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
pSivida and Nicox Enter into Agreement 12
pSivida Enters into Agreement with Major Global Pharmaceutical Company 13
pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 14
pSivida Raises USD17.8 Million in Public Offering of Shares 15
pSivida Raises USD7 Million in Private Placement of Shares 17
pSivida Announces Private Placement Of Shares For US$19 Million 18
pSivida Completes Public Offering Of Shares For US$10.8 Million 19
pSivida Completes Private Placement Of Units For US$5.4 Million 20
pSivida Completes Registered Direct Offering Of Units For US$11 Million 21
pSivida Corp, Key Competitors 23
pSivida Corp, Key Employees 24
pSivida Corp, Subsidiaries 25
